Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Cardiology

Articles with lock require a GLG News subscription
Posted October 4, 2007
Screening: Testing Early for Cholesterol
Analysis of: Screening: Testing Early for Cholesterol | www.nytimes.com
Author: GLG Member Program Contributor
- study from BMJ suggests screening 15 month old toddlers for   hypercholesterolemia - the problem is, there is no treatment for 15 month old toddlers with   hypercholesterolemia
Posted September 27, 2007
St. Jude Medical Announces FDA Approval Of Company's First Radiofrequency Wireless ICD And CRT-D Heart Failure Devices
Analysis of: St. Jude Medical Announces FDA Approval Of Company's First Radiofrequency Wireless ICD And CRT-D Heart Failure Devices | www.medicalnewstoday.com
Author: GLG Member Program Contributor
These products bring St. Jude in Line with Medtronic and Boston Scientific in offering a Wireless platform for their ICD and CRT-D line. The other features listed were generally available in their prior generation of devices, thus do not offer any new capabilities.
Posted September 27, 2007
Early Statin Therapy in Children With Familial Hypercholesterolemia May Yield Large Benefit
Analysis of: Early Statin Therapy in Children With Familial Hypercholesterolemia May Yield Large Benefit | www.medscape.com
Author: GLG Member Program Contributor
It is good to have the possibility to treat children early and slow or stop the development of ASCVD. However, the long-term use of statins starting as early as age 8 means that it will continue for 70+ years in some of these patients.    
Posted September 25, 2007
FDA Proposes CFCs Phase-Out in Epinephrine Inhalers
Analysis of: FDA Proposes CFCs Phase-Out in Epinephrine Inhalers | www.medscape.com
Author: GLG Member Program Contributor
This is a good start. In my opinion there is no place for epinephrine inhalers at all in the treatment of asthma.
Posted September 24, 2007
Shorter Treatment Time For Tuberculosis Using New Antibiotic Drug Combo
Analysis of: Shorter Treatment Time For Tuberculosis Using New Antibiotic Drug Combo | www.medicalnewstoday.com
Author: GLG Member Program Contributor
Any drug that decreases treatment period for TB is good news.
Posted September 24, 2007
Shorter Treatment Time For Tuberculosis Using New Antibiotic Drug Combo
Analysis of: Shorter Treatment Time For Tuberculosis Using New Antibiotic Drug Combo | www.medicalnewstoday.com
Author: GLG Member Program Contributor
TB therapy can be difficult to accomplish. Adherence to therapy is a great barrier. Any regimen that is shorther is likely to improve adherence .
Posted September 24, 2007
Shorter Treatment Time For Tuberculosis Using New Antibiotic Drug Combo
Analysis of: Shorter Treatment Time For Tuberculosis Using New Antibiotic Drug Combo | www.medicalnewstoday.com
Author: GLG Member Program Contributor
- moxifloxacin hasn't had great success, as up to now it has   been another "me-too" drug - this study shows it shortens the time needed to cure tuberculosis   by one third, and saves money to boot - I predict this will become the standard treatment for TB, increasing   sales of moxi...
Posted September 21, 2007
FDA Approves First Generic Versions of Coreg
Analysis of: FDA Approves First Generic Versions of Coreg | www.fda.gov
Author: GLG Member Program Contributor
Market impact is huge for many reasons. First, carvedilol is postulated to be a more effective beta blocker in the management of CHF with reduced ejection fraction compared to other generics and name brand ones on the market. This is based on a number of clinical trials demonstrating superiority in...
Posted September 17, 2007
Dabigatran Etexilate As Effective As Enoxaparin In Lowering Blood Clot Risk After Hip Replacement
Analysis of: Dabigatran Etexilate As Effective As Enoxaparin In Lowering Blood Clot Risk After Hip Replacement | www.medicalnewstoday.com
Author: GLG Member Program Contributor
If results hold up this is clearly an innovation. Taking anything orally is always easier. This will probably reduce costs further as patients will likely be discharged sooner and can stay on anticoagulation longer in a simplified manner.
Posted September 17, 2007
FDA Approves First Generic Versions of Coreg
Analysis of: FDA Approves First Generic Versions of Coreg | www.fda.gov
Author: GLG Member Program Contributor
Coreg is for many the Beta-blocker of choice in the therapy of CHF. A generic version will be cost saving.
Previous Page : 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next131 to 140 of 395

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-08-30T09:45:15.793